Marc Rudoltz brings more than 20 years of clinical drug development experience to his role as Chief Medical Officer at Tango. As the principal of MSR Healthcare Consultants LLC, Marc served as Chief Medical Officer for a number of companies, including Deciphera Pharmaceuticals, Constellation Pharmaceuticals, and as a clinical consultant for Blueprint Medicines. In these roles, Marc led teams to start and accelerate the clinical development of several targeted small molecule anti-cancer agents, including Qinlock®, Aykavit®, Gavreto®, and pelabrisib. Previously, he worked in clinical development roles for several companies, including Novartis, where he played key roles in the development and commercialization of Gleevec® and Tasigna®. Marc obtained his B.S. in Chemical Biology from the Massachusetts Institute of Technology and M.D. from SUNY-Upstate Medical University. He completed residency training in Radiation Oncology at Thomas Jefferson University followed by fellowship training in Cancer Biology at the University of Pennsylvania. Marc is the author of 25 peer-reviewed publications.